* Identified 77 out of 176 circuits in the COVID-19 disease map as differentially activated in infected versus non-infected individuals.
* Identified 46 out of 175 circuits in the COVID-19 disease map as differentially activated in infected versus non-infected individuals.
* Observed high activation in the Interferon-1 pathway, indicative of antiviral defense response. However, not all genes in this pathway are overexpressed, suggesting selective gene-driven activation.
* Noted significant overactivation in the IFN-lambda signaling pathway, aligning with its role in innate antiviral responses and respiratory pathogen activity. This supports targeting this pathway as a potential treatment approach, as evidenced by Feld et al., 2021.
* Found upregulation in the renin-angiotensin pathway, likely due to ACE2's interaction with SARS-CoV-2. This may contribute to increased vasoconstriction, as outlined in Vaduganathan et al., 2020.